Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
IPO Year: 2020
Exchange: NASDAQ
Website: lyratherapeutics.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
5/7/2024 | $12.00 → $2.00 | Buy → Neutral | H.C. Wainwright |
5/7/2024 | $10.00 → $0.50 | Buy → Hold | Jefferies |
5/7/2024 | Buy → Underperform | BofA Securities | |
5/6/2024 | Outperform → Mkt Perform | William Blair | |
10/6/2023 | $15.00 | Buy | BTIG Research |
8/31/2023 | $12.00 | Buy | H.C. Wainwright |
5/24/2022 | $15.00 | Overweight | Cantor Fitzgerald |
SC 13D/A - Lyra Therapeutics, Inc. (0001327273) (Subject)
SC 13G/A - Lyra Therapeutics, Inc. (0001327273) (Subject)
SC 13G/A - Lyra Therapeutics, Inc. (0001327273) (Subject)
SC 13G/A - Lyra Therapeutics, Inc. (0001327273) (Subject)
SC 13G/A - Lyra Therapeutics, Inc. (0001327273) (Subject)
SC 13D/A - Lyra Therapeutics, Inc. (0001327273) (Subject)
SC 13G/A - Lyra Therapeutics, Inc. (0001327273) (Subject)
SC 13G - Lyra Therapeutics, Inc. (0001327273) (Subject)
SC 13G - Lyra Therapeutics, Inc. (0001327273) (Subject)
SC 13G - Lyra Therapeutics, Inc. (0001327273) (Subject)
4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)
4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)
4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)
4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)
4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)
4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)
4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)
4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)
4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)
4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)
https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12036337
In the latest quarter, 4 analysts provided ratings for Lyra Therapeutics (NASDAQ:LYRA), showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 0 2 0 0 Last 30D 0 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 0 2 0 0 3M Ago 1 0 0 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $6.38, with a high estimate of $12.00 and a low estimate of $0.50. A negative shift in sentiment is evident as analysts ha
Cantor Fitzgerald analyst Louise Chen reiterates Lyra Therapeutics (NASDAQ:LYRA) with a Overweight.
- SEC Filing
In the near term, Lyra Therapeutics will focus on the two ongoing ENLIGHTEN Phase 3 trials evaluating LYR-210, a bioabsorbable sinonasal implant for the treatment of chronic rhinosinusitis (CRS). Lyra continues to analyze the data from the ENLIGHTEN 1 trial, which did not meet its 24-week primary endpoint. The Company intends to use this analysis to inform its approach on the completion of the 52-week extension phase of the ENLIGHTEN 1 trial with data expected in Q4 2024 and its approach to the ongoing ENLIGHTEN 2 trial.In connection with the reduction in force, which impacts 87 employees, Lyra Therapeutics has stopped manufacturing and commercialization efforts and seeks to sublease its fac
Gainers Nuwellis (NASDAQ:NUWE) shares rose 57.7% to $0.27 during Tuesday's regular session. The company's market cap stands at $4.1 million. As per the news, the Q1 earnings report came out today. Bioventus (NASDAQ:BVS) stock moved upwards by 28.87% to $5.16. The market value of their outstanding shares is at $329.0 million. The company's, Q1 earnings came out today. Design Therapeutics (NASDAQ:DSGN) stock rose 28.49% to $4.69. The market value of their outstanding shares is at $264.9 million. Acutus Medical (NASDAQ:AFIB) stock moved upwards by 24.11% to $0.13. The company's market cap stands at $3.9 million. Oragenics (AMEX:OGEN) shares moved upwards by 22.78% to $1.33. The market valu
Analysts' ratings for Lyra Therapeutics (NASDAQ:LYRA) over the last quarter vary from bullish to bearish, as provided by 5 analysts. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 0 2 0 0 Last 30D 0 0 2 0 0 1M Ago 1 0 0 0 0 2M Ago 2 0 0 0 0 3M Ago 0 0 0 0 0 Analysts have recently evaluated Lyra Therapeutics and provided 12-month price targets. The average target is $7.5, accompanied by a high estimate of $12.00 and a low estimate of $0.50. A decline of 31.82% from the prior aver
H.C. Wainwright downgraded Lyra Therapeutics from Buy to Neutral and set a new price target of $2.00 from $12.00 previously
Jefferies downgraded Lyra Therapeutics from Buy to Hold and set a new price target of $0.50 from $10.00 previously
BofA Securities downgraded Lyra Therapeutics from Buy to Underperform
William Blair downgraded Lyra Therapeutics from Outperform to Mkt Perform
BTIG Research resumed coverage of Lyra Therapeutics with a rating of Buy and set a new price target of $15.00
H.C. Wainwright initiated coverage of Lyra Therapeutics with a rating of Buy and set a new price target of $12.00
Cantor Fitzgerald initiated coverage of Lyra Therapeutics with a rating of Overweight and set a new price target of $15.00
10-Q - Lyra Therapeutics, Inc. (0001327273) (Filer)
8-K - Lyra Therapeutics, Inc. (0001327273) (Filer)
8-K - Lyra Therapeutics, Inc. (0001327273) (Filer)
8-K - Lyra Therapeutics, Inc. (0001327273) (Filer)
8-K/A - Lyra Therapeutics, Inc. (0001327273) (Filer)
8-K - Lyra Therapeutics, Inc. (0001327273) (Filer)
10-Q - Lyra Therapeutics, Inc. (0001327273) (Filer)
8-K - Lyra Therapeutics, Inc. (0001327273) (Filer)
DEFA14A - Lyra Therapeutics, Inc. (0001327273) (Filer)
DEF 14A - Lyra Therapeutics, Inc. (0001327273) (Filer)
4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)
– Primary focus continues to be on upcoming results from ENLIGHTEN 1 Phase 3 extension study in 4Q 2024 and ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients in 1H 2025, as planned – – In parallel, the company continues to analyze data from ENLIGHTEN 1; further analysis of the ENLIGHTEN 1 data has revealed that LYR-210 demonstrated improvement over control in symptomatic endpoints in the CRS patient cohort with nasal polyps – WATERTOWN, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (NASDAQ:LYRA) ("Lyra" or the "Company"), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusi
WATERTOWN, Mass., April 26, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (NASDAQ:LYRA) (the "Company" or "Lyra"), a clinical-stage biotech developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (CRS), today announced that it has granted non-qualified stock options to purchase a total of 78,400 shares of Lyra Therapeutics common stock to 16 new non-executive employees as an inducement material to their acceptance of employment with Lyra Therapeutics. The employment inducement awards were approved by Lyra's independent directors serving on its Compensation Committee and granted under Lyra's 2022 Employment Inducement Award Plan, as amende
WATERTOWN, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (NASDAQ:LYRA) ("Lyra" or the "Company"), a clinical-stage biotechnology company developing long-acting, anti-inflammatory nasal inserts for the treatment of chronic rhinosinusitis (CRS), today announced that it has granted non-qualified stock options to purchase a total of 119,200 shares of Lyra common stock to 18 new non-executive employees as an inducement material to their acceptance of employment with Lyra. The employment inducement awards were approved by Lyra's independent directors serving on its Compensation Committee and granted under the Company's 2022 Inducement Award Plan, as amended, and related form
WATERTOWN, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (NASDAQ:LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced that Maria Palasis, Ph.D., President and Chief Executive Officer, will participate in the following investor conferences in November: Jefferies London Healthcare Conference 2023 – Fireside chat on Thursday, November 16th at 1:30 p.m. GMTPiper Sandler 35th Annual Healthcare Conference – Presentation on Wednesday, November 29th at 9:30 a.m. ET Live webcast of the presentations will be available on the Investor Relations section of the Company's website at
WATERTOWN, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (NASDAQ:LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced that Maria Palasis, Ph.D., President and Chief Executive Officer, will participate in the following investor conferences in September: H.C. Wainwright 25th Annual Global Investment Conference – Fireside chat on Wednesday, September 13th at 2:00 p.m. ETCantor Global Healthcare Conference 2023 – Fireside chat on Tuesday, September 26th at 4:20 p.m. ET Live webcast of the presentations will be available on the Investor Relations section of the Company's w
WATERTOWN, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (NASDAQ:LYRA) ("Lyra" or the "Company"), a clinical-stage biotechnology company developing long-acting anti-inflammatory therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced that the pivotal Phase 3 ENLIGHTEN I clinical trial of LYR-210 in adult patients with CRS who have not had prior ethmoid sinus surgery, is fully enrolled. LYR-210 is a bioresorbable nasal implant designed to deliver six months of continuous anti-inflammatory medication (mometasone furoate; MF) to the sinonasal passages for the treatment of CRS. Topline results from ENLIGHTEN I are expected in the first half of
WATERTOWN, Mass., July 13, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (NASDAQ:LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of patients with chronic rhinosinusitis (CRS), today announced that Maria Palasis, Ph.D., President and Chief Executive Officer, will present at the William Blair Virtual Biotechnology Conference, "Transitioning Biotech Breakthroughs to Commercial Success," on Tuesday, July 18, 2023 from 10:00 – 10:45 a.m. ET. A replay of the presentation will be available on the Investor Relations section of the Company's website at investors.lyratherapeutics.com for 7 days following the presentation. About Lyra
WATERTOWN, Mass., June 02, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (NASDAQ:LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of patients with chronic rhinosinusitis (CRS), today announced that Maria Palasis, Ph.D., President and Chief Executive Officer, will present at the Jefferies Healthcare Conference in New York, NY on Wednesday, June 7, 2023, at 10:30 a.m. ET. A live webcast of the presentation will be available on the Investor Relations section of the Company's website at investors.lyratherapeutics.com. A replay of the webcast will be available for 30 days following the presentation. About Lyra Therapeutics Lyra Ther
WATERTOWN, Mass., May 26, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (NASDAQ:LYRA) ("Lyra" or the "Company"), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis, today announced that it has entered into a securities purchase agreement to sell securities in a private placement that is expected to result in gross proceeds of approximately $50.0 million, before deducting offering expenses. The closing of the private placement is subject to customary closing conditions and is expected to occur on or about May 31, 2023. Under the terms of the securities purchase agreement, Lyra has agreed to issue and sell (i) app
WATERTOWN, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (NASDAQ:LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of patients with chronic rhinosinusitis (CRS), today announced that Maria Palasis, Ph.D., President and Chief Executive Officer, will present at the Bank of America Securities 2023 Healthcare Conference on Wednesday, May 10, 2023, at 4:35 p.m. PT. A live webcast of the presentation will be available on the Investor Relations section of the Company's website at investors.lyratherapeutics.com. Replays of the webcasts will be available for 30 days following the presentation. About Lyra Therapeutics Lyra